| Price | $25.44 |
| Year Range | $16.91 – $33.77 |
| Market Cap | $1.64B |
| Industry | Biotechnology |
What Is Zenas BioPharma’s AI Stock Analysis?
Zenas BioPharma’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Zenas BioPharma’s momentum in near-real time.
Zenas BioPharma (ZBIO) has an AltIndex AI Score of 47/100, currently a Hold signal. The AI Score distills Zenas BioPharma's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Zenas BioPharma’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Zenas BioPharma — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving ZBIO’s AI Score?
Fundamentals
Revenue for the last quarter was $1M. This is an increase of 0.00% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 0.00%, suggesting positive year-over-year growth. Net income for the last quarter was $-111M. This represents a decrease of 37.62% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 113.42%, which may be a cause for concern. Ebitda for the last quarter was $-101M. This represents a decrease of 35.89% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 93.59%, which may be a cause for concern.
See Zenas BioPharma’s earnings and insider transactions.
Technicals
Today's stock price is $25.44. This represents a decrease of 20.33% compared to a month ago, which may be concerning in the short-term. Compared to a year ago, there is an increase of 5.08%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $26.50, which is lower than the previous SMA10 of $26.74. This suggests a potential downward trend in price movement. The RSI is 64.5, indicating a neutral condition.
See the full technical analysis and price prediction.
Frequently Asked Questions: Zenas BioPharma AI Stock Analysis
Zenas BioPharma's AltIndex AI Score is 47/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Zenas BioPharma a Hold (47/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Zenas BioPharma — company overview, fundamentals, technicals and alternative data, with a recommendation. See the ZBIO AI Score or sign up to read the full thesis.
